Загрузка...
Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome
We report a pediatric patient with atypical hemolytic uremic syndrome due to a C3 gain-of-function mutation diagnosed in infancy. She was treated from the start with a constant dose of 300 mg eculizumab every second week from the onset and followed by routine complement analyses for six years. Her c...
Сохранить в:
| Опубликовано в: : | Case Rep Nephrol |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Hindawi
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6312603/ https://ncbi.nlm.nih.gov/pubmed/30662780 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/3810249 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|